Articles

A dearth of therapies to repair spinal cord damage and reverse paralysis following spinal cord injury spurred a team of researchers to embark on an ambitious project to map the spine as never before.

Editorial Note: This issue of MD News was going to focus on the future of health care. As the magazine content was being prepared and readied for publication, Kansas hospitals and medical practices were focused on responding to a pandemic threat that likely will impact the future financial health and business operations of medical practices and hospitals in Kansas. Therefore, our focus had to also change. With the impact of COVID-19 changing almost daily, our bimonthly publication could refer to just a few of the changes that resulted within a short amount of time.

With older Americans being more at risk for glaucoma and that same population taking multiple prescription medications, it’s important for primary care physicians to understand the side effects and possible drug interactions of the various prescription glaucoma eye drops, says Anita Campbell, MD, a fellowship-trained glaucoma specialist with Grene Vision Group in Wichita.

When seconds matter, count on Ascension Via Christi St. Francis.

About 15 years ago, groundbreaking injections became available as a treatment option for wet age-related macular degeneration (AMD). These injections provide patients with a safer, more sight-sparing treatment option than lasering, or killing off, the abnormal blood vessels formed with wet AMD.

Tens of thousands of Americans apply to U.S. medical schools each year. Only a fraction gain admission. The University of Arizona, for instance, posted a 1.9% acceptance rate in 2018. UCLA, Florida State University and Wake Forest accepted fewer than 3% of applicants.

It makes sense that a former engineer would find robotics surgery fascinating.

The clinical community oncology program led by Ascension Via Christi has joined the Alliance for Clinical Trials in Oncology — part of the National Cancer Institute’s National Clinical Trials Network, or NCTN. It also has a new name: Cancer Research of Kansas.